400-920-2911 sales@csnpharm.cn
SARS-CoV
货号 | 产品名 | CAS号 | 信息 |
---|---|---|---|
CSN29553 | SSAA09E2 | 883944-52-3 | SSAA09E2 is a novel inhibitor of SARS-CoV replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2). |
CSN17457 | PLpro inhibitor | 1093070-14-4 | PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with IC50 of 2.6 μM. |
CSN51370 | PF-00835231 | 870153-29-0 | PF00835231 is a SARS CoV-1 3CLpro inhibitor for potential treatment of COVID-19. |
CSN28746 | (1R,2S,5S)-N-((S)-1-Cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide | 2628280-40-8 | PF-07321332 is an orally active 3CL protease inhibitor, binding covalently and directly to the catalytic cysteine (Cys145) residue of the enzyme. It works as an anti-SARS-CoV-2 drug. |
CSN44050 | ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate | 2492423-29-5 | Molnupiravir is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. |
CSN25551 | ((2R,3S,4R,5R)-3,4-Dihydroxy-5-(4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate | 2635324-86-4 | EIDD-2801 is an orally bioavailable prodrug of EIDD-1931, which has a broad-spectrum antiviral activity against 39 multiple coronaviruses, including SARS-CoV2, MERS-CoV, SARS-CoV. and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor. |
CSN25552 | 1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-4-(hydroxyimino)-3,4-dihydropyrimidin-2(1H)-one | 3258-02-4 | EIDD-1931 has a broad-spectrum antiviral activity against multiple coronaviruses, including SARS-CoV2, MERS-CoV, SARS-CoV. and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor. |
CSN50790 | CCF0058981 | 2708934-53-4 | CCF0058981 is a ML300-derived, non-covalent SARS-CoV‑2 3CLpro inhibitor. |
CSN25478 | 6-Chloro-3-hydroxypyrazine-2-carboxamide | 259793-90-3 | 6-Chloro-3-hydroxypyrazine-2-carboxamide is an intermediate for favipiravir. |
CSN25477 | 6-Bromo-3-hydroxypyrazine-2-carboxamide | 259793-88-9 | 6-Bromo-3-hydroxypyrazine-2-carboxamide is an intermediate for favipiravir. |
CSN25476 | (E)-1-(2-Hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one | 20784-60-5 | 4'-O-Methylbavachalcone is a chalcone isolated from Psoralea corylifolia, which can inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease (PLpro) activity, with an IC50 of 10.1 μM |
CSN60078 | Bemnifosbuvir | 1998705-64-8 |